HER2 amplification and her2 mutation are distinct molecular targets in lung cancers
Academic Article
Overview
MeSH Major
Adenocarcinoma
Genes, erbB-2
Lung Neoplasms
Mutation
abstract
HER2 mutations are not associated with HER2 amplification, thus suggesting a distinct entity and therapeutic target. HER2-positive lung cancer may not be an adequate term, and patient cohorts for the study of HER2-targeted agents should be defined by the specific HER2 alteration present.
